Other studies have also reported that the inhibition of NF-kB using IKKβ inhibitors ameliorated the pathogenesis in many fibrotic diseases, including lung fibrosis [15-17], hepatic fibrosis [18,19], and skin proliferative disorders [20,21]. This evidence concerns the gene NFKB1 and Hepatic fibrosis.